Sorrento Therapeutics has nabbed a partnership with France’s Servier to develop products based on Sorrento’s immuno-oncology anti-PD-1 monoclonal antibody STI-…

AstraZeneca has released $62 million for a license payment to partner FibroGen ($FGEN) as its experimental pill roxadustat continues its late-stage testing for…

Carmot Therapeutics has secured its second major partnership. The latest is a discovery and licensing deal with Roche’s Genentech.

Vertex and Moderna have partnered in a deal potentially worth more than $300 million to discover and develop messenger RNA therapeutics for cystic fibrosis.

Less than a week after stumping up cash for a one-drug-wonder biotech (and an option to buy it out), Japan’s Takeda has struck another biotech deal, this time…

Bristol-Myers Squibb and PsiOxus Therapeutics have partnered to put a pair of candidates into Phase I testing to treat several tumor types in late-stage cancer…

Herbert Stadler’s Ellersbrook has partnered with Evotec to take a NASH program to the point it can be spun out or flipped to a biopharma company.

Despite the problems in China, Pfizer is betting big on its first biotech space in the region, stumping up £$350 million for a new biotech center that it hopes…